Lilly and Hims & Hers broaden access to Lilly’s Zepbound and Foundayo
- Agreement covers Zepbound (tirzepatide) and Foundayo (orforglipron).
- Self-pay pricing starts at $149/month for Foundayo and $299/month for Zepbound.
- Patients complete a consultation on Hims & Hers, may receive a prescription, and have FDA‑approved medicine shipped to their home.
- Hims & Hers has committed not to offer compounded copies of Lilly’s GLP‑1s and to protect independent clinical decision‑making.
Deal overview
Eli Lilly and Hims & Hers agreed to expand access to Lilly’s FDA‑approved medicines Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers platform, giving eligible patients a path to self‑pay pricing while remaining on the platform.
Patient experience and pricing
Patients can complete a consultation with a licensed provider on Hims & Hers, receive a prescription if the provider determines it appropriate, and have the FDA‑approved Lilly medicine shipped directly to their home. Self‑pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.
Platform services and safeguards
Hims & Hers will support customers with membership features including 24/7 access to a care team, nutrition guidance, regular clinical check‑ins, and a weight loss community. The companies said Hims & Hers has never offered— and has committed not to offer—compounded copies of Lilly’s GLP‑1s, and that providers on the platform will retain independent clinical decision‑making.
Context and statements
The companies framed the agreement around growing patient interest in telehealth for obesity care and Lilly’s broader portfolio of GLP‑1 treatments. Lilly and Hims & Hers leaders highlighted the partnership as a way to meet patients where they seek care and expand access to FDA‑approved medicines.
Source: Lilly